Open-label, single arm study of short term Trastuzumab and Pertuzumab in combination with taxanes in adjuvant treatment of HER2-positive early breast cancer

Start Date06 Nov 2023

Sponsor / Collaborator

Ruijin Hospital

IRCT20201203049585N3

/ SuspendedPhase 2/3IIT

the effect of high power laser therapy on neuropathy induced by chemotherapy with taxane drugs in breast cancer patients

Start Date23 Aug 2023

Sponsor / Collaborator

Isfahan University of Medical Sciences

JPRN-UMIN000042218

/ CompletedNot Applicable

The efficacy and safety of taxane therapy after discontinuation of nivolumab therapy in Japanese patients with advanced or recurrent esophageal cancer:a retrospective observational study (AFTER NIVO ESO Study) - AFTER NIVO ESO study

Start Date01 Jan 2021

Sponsor / Collaborator-

100 Clinical Results associated with Taxane

100 Translational Medicine associated with Taxane

100 Patents (Medical) associated with Taxane

7,309

Literatures (Medical) associated with Taxane

01 Jul 2025·DRUG RESISTANCE UPDATES

Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies

Review

Author: Corbeau, Iléana ; Perego, Paola ; Beretta, Giovanni Luca ; Rossi, Giacomina ; Azzariti, Amalia ; Cassinelli, Giuliana ; Tosi, Diego

Taxanes are effective in several solid tumors. Paclitaxel, the main clinically available taxane, was approved in the early nineties, for the treatment of ovarian cancer and later on, together with the analogs docetaxel and cabazitaxel, for other malignancies. By interfering with microtubule function and impairing the separation of sister cells at mitosis, taxanes act as antimitotic agents, thereby counteracting the high proliferation rate of cancer cells. The action of taxanes goes beyond their antimitotic function because their main cellular targets, the microtubules, participate in multiple processes such as intracellular transport and cell shape maintenance. The clinical efficacy of taxanes is limited by the development of multiple resistance mechanisms. Among these, extracellular vesicles have emerged as new players. In addition, taxane metronomic schedules shows an impact on the tumor microenvironment reflected by antiangiogenic and immunomodulatory effects, an aspect of growing interest considering their inclusion in treatment regimens with immunotherapeutics. Preclinical studies have paved the bases for synergistic combinations of taxanes both with conventional and targeted agents. A variety of drug delivery strategies have provided novel opportunities to increase the drug activity. The ability of taxanes to orchestrate different cellular effects amenable to modulation suggests novel options to improve cures in lethal malignancies.

01 Jul 2025·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Review of the contribution of clinical and genetic factors to the racial disparity in taxane-induced peripheral neuropathy

Review

Author: Hertz, Daniel L ; Trivedi, Meghna S ; Schneider, Bryan P ; Nazzal, Maisa ; Nguyen-Hoang, Nam

Taxanes are first-line chemotherapy for several solid tumors, but their use is often limited by taxane-induced peripheral neuropathy (TIPN), which can cause acute symptoms in up to 70 % of patients and severely deteriorate long-term quality of life. Recent evidence from large prospective observational studies confirms a dramatic racial disparity, with Black/African-ancestry patients facing roughly two times greater risk of TIPN compared to White patients. Understanding the root causes of this disparity is a critical first step toward eliminating inequities in cancer treatment side effects, aligning with a major goal of the U.S. National Cancer Institute's National Cancer Plan. This review examines clinical and genetic factors contributing to racial differences in TIPN, focusing on those that have been associated with TIPN risk and are more prevalent within Black/African-ancestry individuals. Pre-existing neuropathy, vitamin D insufficiency, metabolic risk factors (obesity/diabetes), systemic taxane exposure, and genetic variants are discussed as potential contributors to this racial disparity. The review concludes by describing additional research that is needed to determine which of these factors are responsible for this disparity and what types of translational clinical studies could be conducted to target these mechanisms and reduce inequity. These findings could inform clinical strategies that improve long-term quality of life and promote health equity in taxane-treated cancer patients in the U.S. and globally.

01 Jul 2025·CANCER LETTERS

Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes

Article

Author: Modi, Gaurang ; Khatwani, Itesh ; Pathak, Anand ; Karpe, Ashay ; Thavarool, Sajith Babu ; Gupta, Tara Chand ; Wilson, Lovin ; Rajamanickam, Deepan ; Turkar, Siddharth ; Shenoy Vp, Praveen Kumar ; Singh, Gunjesh ; Jadhav, Monica ; Prabhash, Kumar ; Mandal, Tanmoy Kumar ; Bhosale, Bharat ; Pande, Nikhil ; Jha, Bhavya ; Poladia, Bhavesh ; Katna, Rakesh ; Talreja, Vikas T ; Rajamanickam, Saravana ; Chandrasekharan, Arun ; Bhagyavant, Priyanka ; Avaronnan, Manuprasad ; Das, Sudeep ; Muley, Sonal ; Singh, Unnati ; Sonwani, Vaibhav ; Madankar, Kamlesh ; Peelay, Zoya ; Raut, Nirmal ; Kolkur, Manali ; Alone, Mitali ; Patil, Vijay ; Noronha, Vanita ; Pathak, Shruti ; Sen, Nibedita ; Kothari, Rushabh ; Singh, Ravikant ; Banavali, S D ; Kumar, Gautam ; Bhatt, Palak ; Madala, Ravi Krishna ; Shrirangwar, Sameer

There are multiple options of treatment in second line therapy for locally advanced head and neck squamous cell carcinoma (LAHNSCC) treated with palliative intent. However, triple metronomic chemotherapy is oral, cost-effective, and resource-efficient. Hence this phase 3 randomized trial compares National Comprehensive Cancer Network (NCCN) recommended physician choice therapy versus triple metronomic chemotherapy (TMC) in the second-line treatment of head and neck cancer This study, designed to establish superiority, was conducted in India across 16 sites under the Cancer Research Statistics Foundation. The study recruited 114 LAHNSCC who were treated with palliative intent in second line. These patients underwent 1:1 central stratified randomization to either triple metronomic chemotherapy or physician choice therapy (taxane, 5fu/capecitabine, afatinib, nivolumab/pembrolizumab, cetuximab).At a median follow-up of 258 (95 % CI 209-306) days, the median overall survival of the triple metronomic chemotherapy was 181 days (95 %CI 142.7-219.2) versus 123 days (95 %CI 94-152) in the physician choice therapy arm (P = 0.00.002). The median progression free survival was 120 days (95 %CI 89.2-150.8) versus 70 days (95 % CI 58.2-81.8) in metronomic chemotherapy and in the physician choice therapy arms respectively (P < 0.001).These results suggest that TMC significantly improves survival outcomes over physician choice therapy in platinum-refractory head and neck cancer.

155

News (Medical) associated with Taxane

15 May 2025

·www.globenewswire.com

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary endpoint results provide insights into use in earlier settingsFabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5Ianalumab Phase II data in immune thrombocytopenia and longer-term pelabresib Phase III data in myelofibrosis show breadth of pipeline in hematologic diseases Basel, May 15, 2025 – Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2025 Congress. “The breadth of our oncology and hematology portfolio – anchored by Kisqali, Pluvicto, Scemblix and Fabhalta – demonstrates our leadership in both solid tumors and hematologic diseases,” said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer, Novartis. “At ASCO and EHA, we will present new data on these priority medicines as well as updates from our pipeline and our industry-leading radioligand therapy research.” Novartis will also highlight its US partnerships with the National Football League (NFL), Alliance for Breast Cancer Policy, and ZERO Prostate Cancer, which encourage people to make proactive decisions about their health and advance patient-centered policy solutions to help improve outcomes. “We're witnessing a profound shift in how people move through their cancer journey, with cancer diagnoses occurring at younger ages and, simultaneously, older patients living longer and approaching aging with new vigor,” said Victor Bultó, President, US, Novartis. “As a leader in driving medical advances in oncology, we have the responsibility to also make a difference in areas beyond treatment innovation. By partnering across the ecosystem, our goal is to advance the conversation around earlier detection and meet the evolving needs of this next generation of cancer patients.” Key highlights of data accepted by ASCO include: Medicine Abstract Title Abstract Number/ Presentation Details Kisqali®(ribociclib)* Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: Analysis across menopausal status and age Abstract #516Rapid OralJune 1, 8:00 – 9:30am CDT Kisqali®(ribociclib) Real-world (RW) analysis of characteristics and risk of recurrence (ROR) in Black patients (pts) with HR+/HER2− early breast cancer (EBC) eligible for NATALEE Abstract #527Poster PresentationJune 2, 9:00am – 12:00pm CDT Kisqali®(ribociclib) Adjuvant WIDER: A phase 3b trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to-clinical-practice patient (pt) population with HR+/HER2− early breast cancer (EBC) Abstract #TPS617Poster PresentationJune 2, 9:00am – 12:00pm CDT Kisqali®(ribociclib) First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice Abstract #1069Poster PresentationJune 2, 9:00am – 12:00pm CDT Scemblix®(asciminib) Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial Abstract #6516Rapid OralMay 30, 1:00 – 2:30pm CDT Scemblix® (asciminib) Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE) Abstract #6501Oral PresentationJune 2, 3:00 – 6:00pm CDT Pluvicto®(lutetium Lu 177 vipivotide tetraxetan) Clinical outcomes of prompt versus deferred 177Lu-PSMA-617 initiation for metastatic castration-resistant prostate cancer (mCRPC) based on prior androgen receptor pathway inhibitor (ARPI) and taxane chemotherapy exposure: a real-world PRostatE Cancer dISease observatION (PRECISION) data platform analysis Abstract #e17030Online Publication Pluvicto®(lutetium Lu 177 vipivotide tetraxetan) Real-world outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) receiving guideline-recommended therapies after treatment with 177Lu-PSMA-617: a real-world PRostatE Cancer dISease observatION (PRECISION) data platform analysis Abstract #e17035Online Publication Pluvicto®(lutetium Lu 177 vipivotide tetraxetan) PSMA-delay castration (DC): An open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC) Abstract #TPS5127Poster PresentationJune 2, 9:00am – 12:00pm CDT Key highlights of data accepted by EHA include: Medicine Abstract Title Abstract Number/ Presentation Details Fabhalta®(iptacopan) APPULSE-PNH: Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin (Hb) increases in patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) and Hb ≥10 g/dL on anti-C5 therapy Abstract #S183Oral PresentationJune 13, 5:00 – 6:15pm CEST Fabhalta®(iptacopan) The 2-year safety and efficacy of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria (PNH) from APPLY- and APPOINT-PNH studies who entered the roll-over extension program (REP) Abstract #PF660Poster PresentationJune 13, 6:30 – 7:30pm CEST Scemblix®(asciminib) Asciminib (ASC) shows superior tolerability vs nilotinib (NIL) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Primary endpoint results of the phase (Ph) 3b ASC4START trial Abstract #S166Oral PresentationJune 13, 5:00 – 6:25pm CEST Scemblix®(asciminib) Improved patient-reported outcomes (PROs) with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST wk 48 analysis Abstract #PS1588Poster PresentationJune 14, 6:30 – 7:30pm CEST Scemblix®(asciminib) Interim analysis (IA) results from ASC2ESCALATE support asciminib (ASC) as a treatment (Tx) option in chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI) Abstract #PF595Poster PresentationJune 13, 6:30 – 7:30pm CEST Pelabresib(DAK539) Pelabresib in combination with ruxolitinib for janus kinase inhibitor-naive patients with myelofibrosis: 72-week follow-up with long-term efficacy outcomes of the phase III MANIFEST-2 study Abstract #S223Oral PresentationJune 12, 5:00 – 6:15pm CEST Ianalumab(VAY736) A Phase 2 Study of Ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy (VAYHIT3) Abstract #S312Oral PresentationJune 15, 11:00am – 12:15pm CEST Rapcabtagene autoleucel (YTB323) Rapcabtagene Autoleucel (YTB323) in patients with relapsed/refractory diffuse large B-cell lymphoma: A phase II trial clinical update Abstract #PF1152Poster PresentationJune 13, 6:30 – 7:30pm CEST Novartis in oncologyThe Novartis oncology strategy focuses on people living with cancer and those who care for them, from loved ones to clinical care teams, including their providers. For the past 30+ years, the aim has been to extend and improve lives by discovering differentiated, innovative and practice-changing medicines for patients. As Novartis reimagines medicine, it collaborates with a wide range of patient advocacy groups and supports education, early cancer screening and diagnosis, all while innovating at a rate that is unparalleled in the industry. With approximately 35 research and development projects across solid tumors, hematology and radioligand therapy (RLT), Novartis is committed to using technology, leading science and patient-centered research to deliver pioneering cancer care for all those in need. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. # # # *Kisqali was developed by Novartis under a research collaboration with Astex Pharmaceuticals. Novartis Media RelationsE-mail: media.relations@novartis.com Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com

Phase 2ASCOPhase 3Clinical Result

07 May 2025

·firstwordpharma.com

AstraZeneca, Daiichi's Enhertu extends winning streak in breast cancer trials, this time in neoadjuvant setting

AstraZeneca and Daiichi Sankyo on Wednesday said their antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) hit the main goal of yet another pivotal breast cancer study, this time demonstrating superior response rates over standard therapy in the neoadjuvant setting for patients with high-risk HER2-positive early-stage breast cancer.The Phase III DESTINY-Breast11 study enrolled 927 patients, who were randomised to receive either Enhertu monotherapy, Enhertu followed by the THP regimen comprising the taxane paclitaxel, Roche’s Herceptin (trastuzumab) and Perjeta (pertuzumab), or the current standard-of-care (SOC) regimen of dose-dense doxorubicin and cyclophosphamide followed by THP (ddAC-THP) in the neoadjuvant setting.Top-line results showed that Enhertu followed by THP significantly improved pathologic complete response rates — defined as the absence of invasive cancer cells in breast tissue and lymph nodes post-treatment — compared with the ddAC-THP regimen. The companies also noted a positive trend on the secondary endpoint of event-free survival favouring Enhertu, though these data remain immature.“Enhertu is already an important treatment option in the metastatic setting, and these data have the potential to allow this medicine to move into early stages of disease where cure is possible,” remarked Susan Galbraith, executive vice president of oncology haematology R&D at AstraZeneca.Meanwhile, the HER2-directed ADC demonstrated an improved tolerability profile versus SOC, with no new safety concerns identified — interstitial lung disease rates were comparable between the treatment arms. Detailed data from the study will be presented at an upcoming conference and submitted to regulatory agencies. Enhertu first received FDA approval in 2019 for unresectable or metastatic HER2-positive breast cancer in patients previously treated with at least two anti-HER2 regimens. Its label was later expanded to include HER2-low disease in the second-line setting based on results from the Phase III DESTINY-Breast04 study, and HER2-ultralow patients backed by data from DESTINY-Breast06. Last month, the ADC also demonstrated a progression-free survival benefit in previously untreated patients with HER2-positive metastatic breast cancer in the DESTINY-Breast09 trial.

Clinical ResultADCPhase 3Drug Approval

05 May 2025

·pipelinereview.com

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

SAN DIEGO, CA, USA I May 05, 2025 I Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the initiation of Phase 1b expansion studies in the ongoing ENGAGER-PSMA-01 trial. ENGAGER-PSMA-01 is a first-in-human, open-label, multicenter Phase 1 clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX007 administered as monotherapy or in combination in adult patients with advanced metastatic castration-resistant prostate cancer (mCRPC). In December 2024, Janux reported positive interim clinical data from the Phase 1a dose escalation portion of the trial in 16 mCRPC patients with a median of four prior lines of therapy. At that time, the median radiographic progression-free survival (rPFS) reported was 7.4 months for all 16 patients.* As of April 21, 2025, updated results** have been achieved in the same 16 patients supporting the initiation of the Phase 1b expansion studies: *8/16 patients were noted as in-progress in the December 2024 reported results. **rPFS results based upon Kaplan-Meier estimate. In addition, Janux has selected a CRS-mitigation strategy to support the initiation of the Phase 1b expansion studies that is designed to maintain the CRS profile reported in December. The first Phase 1b expansion study will enroll taxane-naïve mCRPC patients and is designed to generate additional safety and efficacy data in this first and second line (1L/2L) patient population. This study will assess JANX007 monotherapy at two dose regimens (0.3/2/6mg and 0.3/2/9mg) with dosing administered once weekly or once every two weeks in mCRPC patients who have progressed on or after novel hormonal therapy (NHT). “Initiation of the taxane-naïve study marks an important step as we begin to evaluate JANX007 in earlier-line mCRPC patient populations,” said Zachariah McIver, D.O., Ph.D., Chief Medical Officer of Janux. “While therapeutic options for mCRPC have expanded, there remains a significant need for novel, non-chemotherapeutic approaches.” Janux plans to initiate three additional Phase 1b expansion studies, evaluating: “Improved efficacy and durability of responses has been observed by other prostate cancer drugs and TCEs when moving into earlier lines of therapy. There are also indications that safety with TCEs improve in earlier lines of therapy where disease burden is lower. We believe that these observations, coupled with the data seen in our Phase 1a dose escalation in later line patients, strongly support our decision to develop JANX007 in earlier lines of therapy,” said David Campbell, Ph.D., President and CEO of Janux. Additional data from JANX007 and JANX008 will be presented at future Janux events in the second half of 2025. Separately, Janux will host an R&D Day in mid-2025 highlighting product candidates identified from its preclinical pipeline to move into clinical trials. Janux’s TRACTr and TRACIr Pipeline Janux’s first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with metastatic castration-resistant prostate cancer. Janux’s second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. We are also generating a number of additional TRACTr and TRACIr programs for potential future development, some of which are at development candidate stage or later. We are currently assessing priorities in our preclinical pipeline. About Janux Therapeutics Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux’s proprietary technology enabled the development of two distinct bispecific platforms: TRACTr and TRACIr. The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Janux is currently developing a broad pipeline of TRACTr and TRACIr therapeutics directed at several targets to treat solid tumors. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. For more information, please visit www.januxrx.com and follow us on LinkedIn. SOURCE: Janux Therapeutics

Phase 1ImmunotherapyClinical Result

100 Deals associated with Taxane

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Phase 3	Germany	Martin-Luther-Universität Halle-Wittenberg	31 Jan 2002
Brain metastases	Phase 2	China	Second Affiliated Hospital of Zhengzhou University	01 Oct 2021
Triple Negative Breast Cancer	Phase 2	Russia	Russian Academy of Medical Sciences	31 Aug 2011
HER2 Positive Breast Cancer	Phase 2	Australia	Hoffmann-La Roche, Inc.	13 Aug 2009
HER2 Positive Breast Cancer	Phase 2	Spain	Hoffmann-La Roche, Inc.	13 Aug 2009
HER2 Positive Breast Cancer	Phase 2	Sweden	Hoffmann-La Roche, Inc.	13 Aug 2009
HER2 Positive Breast Cancer	Phase 2	United Kingdom	Hoffmann-La Roche, Inc.	13 Aug 2009
Fallopian Tube Carcinoma	Phase 2	China	Shanghai Jiao Tong University	30 Apr 2009
Fallopian Tube Carcinoma	Phase 2	China	Fudan University	30 Apr 2009
Follicular Adenocarcinoma	Phase 2	China	Fudan University	30 Apr 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SABCS2023	Not Applicable	Breast Cancer Lymphedema Adjuvant	1,759	Taxane-based chemotherapy	bbzssmfoaw(itoyirbvyh) = obfswrpqxj sgkcqwlmft (rgbbtifjjx )	Positive	01 Mar 2023
				Non-taxane chemotherapy	-
SABCS2023	Not Applicable	Triple Negative Breast Cancer Neoadjuvant HER2 expression	143	Anthracycline and Taxane-based chemotherapy	jlxsdmbfgk(dvnpgxkwmt) = bwvhnmmdll vdzoxpeyfr (obczvkcwrl ) View more	-	01 Mar 2023
				Anthracycline and Taxane-based chemotherapy + Carboplatin	tcpteemthn(uantogpymn) = zsxydbcufo idbpmhwfdv (lbguhuopxe ) View more
Pubmed \| Breast	Not Applicable	HER2-negative breast cancer First line HER2-negative \| hormone-receptor positive	1,057	Taxanes without bevacizumab	dsdozgygxb(wibweekqpc): HZR = 1.3 View more	Negative	01 Oct 2022
				Other chemotherapies
WCLC2022	Not Applicable	Advanced Lung Non-Small Cell Carcinoma	467	Taxane monotherapy	nylfshkotv(rfleswdqyp) = xlmgcxydql loobqlzthg (rzeisocjdl, 8.1 - 11.2)	-	06 Aug 2022
				Taxane-containing combination	nylfshkotv(rfleswdqyp) = acwpywoocn loobqlzthg (rzeisocjdl, 7.5 - 9.6)
SABCS2020	Not Applicable	Early Stage Breast Carcinoma Adjuvant diabetes	176	Paclitaxel	hlkzcpnskh(zhgiwokqfi) = aupjtfnbxj lmiwgeiguc (lrbyjijhxa )	-	15 Feb 2020
ASCO2018	Not Applicable	Esophageal Carcinoma	412	Docetaxel (DF)	enpolqevqr(yudscmavdy) = ihutpmpfcn vkmaxnavqs (kxictftphh, 38.6 - 70.3) View more	Positive	01 Jun 2018
				Oxaliplatin (FOX)	enpolqevqr(yudscmavdy) = gaztpxgvwh vkmaxnavqs (kxictftphh, 18.1 - 70.4) View more
SABCS2018	Not Applicable	Breast Cancer Neoadjuvant \| Adjuvant	79	Neoadjuvant chemotherapy	uzmhblvgmp(cjjvhtmkqn) = reported in 2 pts (1.3%) each kofwuymvcz (erxywpociz ) View more	Positive	15 Feb 2018
				Adjuvant chemotherapy
ASTRO2017	Not Applicable	Esophageal Carcinoma	-	Platinum-based/5-fluorouracil (PF)	hrekrofxrf(uiouuiqwgv) = ikgycteuav uroueibkuh (bztkrdgvbh ) View more	-	01 Oct 2017
				Taxane-based/5-fluorouracil (TF)	hrekrofxrf(uiouuiqwgv) = cvamkrunlu uroueibkuh (bztkrdgvbh ) View more
ASTRO2014	Not Applicable	Uterine Serous Carcinoma	-	Taxane (UPSC)	wtgsixtdqb(gqkjxwxezw) = slpelzjpjo tkmindywkj (pqqfurstvs, 3 - 16)	-	01 Sep 2014
				Taxane (CS)	wtgsixtdqb(gqkjxwxezw) = vmbwkdksxd tkmindywkj (pqqfurstvs, 2 - 30)
AACR2013	Not Applicable	Recurrent Metastatic Gastric Carcinoma First line	146	taxane-based (TUBB3 high expression)	zfjblewgmm(vgbdsbwmis) = zfdbkhamlo wzykmxcoed (xjlynqgaeb ) View more	-	15 Apr 2013
				taxane-based (TUBB3 low expression)	zfjblewgmm(vgbdsbwmis) = zojstiqfaq wzykmxcoed (xjlynqgaeb ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Taxane

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation